Background: Omega-3 and omega-6 fatty acids are commonly used in pregnancy, lactation, and malnutrition. Paediatrics has been investigating whether omega-3/omega-6 supplementation affects human growth and neurodevelopment in recent decades.Aims: To assess the current state of knowledge regarding the use of omega-3/omega-6 type fatty acids in the diet in adolescent and adult populations.Materials and Methods: Through September 2022, Pubmed has chosen 72 original articles on the topic of human growth and nutrition in paediatrics.Results: According to the literature, the use of omega-3/omega-6 fatty acids, with a higher prevalence in the former group than the latter, appears to be most effective in hypertension, dyslipidemia, and high C-reactive protein values, cardiovascular risk, and neuropatic pain, while having less impact on neurodegenerative (except in multiple sclerosis) and mental disorders (except in depression). Combining omega-3 and omega-6 fatty acids with spirulina algae, chitosan, probiotics, vitamin D, fibre, and plant extracts yields intriguing results.Conclusions: Although significant evidence emerges on the importance of omega-3 and omega-6 fatty acid supplementation, significant structural flaws in research designs continue to emerge from published studies; additionally, many studies assume that fatty acid supplementation can have a curative effect on already active diseases, when in fact such prescriptions should be considered as adjuvant therapies to prevent or promote symptomatic regression, precisely because of their fatty acid content. Future research that can address the critical issues raised is hoped to promote a more comprehensive approach to the topic of omega-3/omega-6 supplementation in human health.

Despite varying findings, TST has been used for a long time to treat hypogonadal males with type 2 diabetes mellitus (T2DM). The function of TST was evaluated in this meta-analysis in hypogonadal males with type 2 diabetes. Relevant randomised controlled trials and observational studies were identified by searching PubMed, Embase, and Google Scholar. The effects of TST were evaluated using pooled mean differences (MDs) and relative risks with 95% confidence intervals (CIs).Our meta-analysis includes 3,002 hypogonadal, type 2 diabetics from 13 randomised controlled trials and 2 observational studies. Total testosterone levels increase significantly with testosterone replacement, and TST significantly improves glycemic management compared to placebo by lowering homeostatic model assessment of insulin resistance (WMD = -1.47 [-3.14, 0.19]; p=0.08; I2=56.3%), fasting glucose (WMD = -0.30 [-0.75, 0.15]; p=0.19; I2= 84.4%), fasting insulin (WMD = -2.95 [-8. Overall, TST resulted in a greater increase in free testosterone levels compared to placebo (WMD = 81.21 [23.87, 138.54] p=0.07; I2= 70%) when comparing patients' individual measurements.We conclude that TST can help hypogonadal Type 2 Diabetes patients with better glycemic control and hormone levels, as well as lower total cholesterol, triglyceride, and LDL cholesterol while raising HDL cholesterol. Therefore, in addition to the usual care for diabetes, we advise TST for these individuals.

No abstract